Santiago Isorna

Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model

J.M. Fernández Gómez, Rosário Madero, Eduardo Solsona et al. · The Journal of Urology · 2009 · 639 citations · Full text

Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

Urs E. Studer, Peter Whelan, Walter Albrecht et al. · Journal of Clinical Oncology · 2006 · 330 citations

Prognostic Factors in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials

J.M. Fernández Gómez, Eduardo Solsona, Miguel Unda et al. · European Urology · 2007 · 254 citations · Full text

Prognostic Factors, Urology, Bacillus Calmette-guérin +9

Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer

J.A. Martínez‐Pin ̃eiro, N Flores, Santiago Isorna et al. · British Journal of Urology · 2002 · 211 citations

A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C

Antonio Ojea, José Luís Nogueira, Eduardo Solsona et al. · European Urology · 2007 · 204 citations

Urology, Surgical Oncology, Genitourinary Cancer +6